In 2004, the United States released a report on osteoporosis recommending that physicians adopt a pyramidal approach to therapy. The base of the pyramid includes calcium, vitamin D, physical therapy and fall prevention. The second level calls for management or elimination of secondary causes of osteoporosis. The third level consists of treatment with either anti-resorptive or anabolic medications.
The trouble is osteoporosis is a "silent disease", because there are no symptoms prior to a fracture. However, once a person has broken a bone, their risk of breaking another fragility fracture increases significantly. After the first break, one in eight will break another bone within a year and a quarter within five years.
This article reviews the available nonpharmacologic and pharmacologic interventions -proved to be effective that may be implemented to reduce the risk of osteoporotic fractures.
Epidemiology
Reduced bone density is a major risk factor for fragility fracture. Other factors that may affect the risk of fragility fracture include the use of oral or systemic glucocorticoids, age, sex, previous fractures, and family history of osteoporosis. 2 Because of increased bone loss after the menopause in women, and age-related bone loss in both women and men, the prevalence of osteoporosis increases markedly with age, from 2% at 50 years to more than 25% at 80 years in women. 2 The National Institute for Health and Clinical Excellence (NICE) estimates there are 2 million women who have osteoporosis in England and Wales. 1 
What is Bone density?
Bone density values in individuals can be expressed in relation to a reference population in standard deviation(SD); when compared to the young healthy population, this measurement is referred to as the Tscore. 3 Osteoporosis: T-Score 2.5 SD or more below is called osteoporosis .Severe osteoporosis: T-Score 2.5 SD or more below in thepresence of one or more fragility fractures (T-score d"-2.5 PLUS fracture).
Osteopenia: T-score less than -1 but above -2.5
Normal: T-score >-1.
Risk factors for reduced BMD are:
• Female gender.
• Low body mass (<19 kg/m2) and anorexia nervosa.
• Smoking.
• Alcohol intake of four or more units per day • Poor diet (particularly if calcium-deficient) or malabsorption syndromes, eg coeliac disease.
• Prolonged immobilisation.
• Caucasian or Asian origin
• Parental history of hip fracture.
• Corticosteroid therapy or Cushing's syndrome.
• Ankylosing spondylitis.
• Rheumatoid arthritis.
• Crohn's disease.
• Premature menopause (<45 years) or prolonged secondary amenorrhoea.
• Primary hypogonadism (men and women).
• Primary hyperparathyroidism.
• Hyperthyroidism.
• Osteogenesisimperfecta.
• Post transplantation.
• Chronic renal failure.
Clinical Presentation
In most of the cases osteoporosis is asymptomatic and the condition usually presents only after bone fracture. It is important that clinicians be alert to recognise low trauma 'fragility fractures'. 1 Fragility fractures occur most commonly in the spine (vertebrae), hip (proximal femur), and wrist (distal radius). They may also occur in the arm (humerus), pelvis, ribs, and other bones. 2 Signs differ according to the fracture site.
Investigations
• If a fragility fracture occurs this should trigger bone density measurement.
• Patients with any risk factors above should be considered for DEXA scanning, particularly if there are one or more risk factors for fractures (family history, increased alcohol intake or rheumatoid arthritis).
• DEXA is regarded as the gold standard technique for diagnosis; the accuracy at the hip exceeds 90%. There is now a WHO risk calculator available (FRAX) which calculates the ten-year probability of a major osteoporotic fracture, (with or without BMD result). 7, 8 For UK populations, the recent Fracture score may be more appropriate for fracture risk assessment. 9,10
Management 1
Treatment for osteoporosis should include not only drug treatment but also advice on lifestyle, nutrition, exercise and measures to reduce falls. Ensure adequate calcium intake and vitamin D status, prescribing supplements if required. 11 Patients with osteoporosis (T-score -2.5 or worse) at any age:
Consider hip protectors and assessment of ongoing risk of falls.
Reduce polypharmacy, especially sedatives.
Ensure adequate calcium (0.5-1 g) and vitamin D (800 IU) -supplementation may be necessary.
Bisphosphonates are the mainstay of treatment for osteoporosis. They are, however, poorlyabsorbed and need to be taken separately from food. They may cause oesophageal irritation and should be taken by the patient sitting up with plenty of water. 11 Etidronate was the first but has beensuperseded by the more powerful alendronate and risedronate, both of which can be taken daily or weekly, and the newer ibandronate that can be taken monthly. 14 Following are the different options of Bisphosphonate:
Alendronate:
• Can increase bone mass and reduce chances of spine, hip and other fractures.
• Available in daily and weekly doses.
Zoledronic acid:
• Available as an intravenous injection given once yearly.
Side effects for oral bisphosphonates include gastrointestinal problems such as difficulty swallowing, inflammation of the esophagus and stomach ulcers.
Side effects for intravenous bisphosphonates include flu-like symptoms, fever, pain in muscles or joints, and headache. These side effects can occur shortly after receiving an infusion and generally stop within two to three days.
There also have been rare reports of osteonecrosis of the jaw and of visual problems in people taking oral and intravenous bisphosphonates.
Raloxifene
Raloxifene, approved by the FDA for the prevention and treatment of osteoporosis for women after menopause, belongs to a class of drugs called selective estrogen receptor modulators (SERMs). It has estrogenlike effects on the skeleton, but blocks estrogen effects in the breast and uterus. It slows bone loss and reduces risk of fractures in the spine, but no effect on hip fractures has been seen.
Side effects are not common but hot flashes and DVT may occur.
Calcitonin
Calcitonin, is a naturally occurring hormone that helps to regulate S.calcium levels.
In women who are at least five years past menopause, calcitonin slows bone loss, increases spinal bone density, reduces the risk of spinal fractures, and may relieve the pain associated with bone fractures. Calcitonin is available as an injection (IM/IV) or as a daily nasal spray.
Injectable calcitonin may cause an allergic reaction and unpleasant side effects including flushing of the face and hands, frequent urination, nausea, and skin rash. The only side effect reported with nasal calcitonin is nasal irritation.
Teriparatide
It is an injectable form of human parathyroid hormone, is approved for postmenopausal women and men with osteoporosis who are at high risk for having a fracture.
Unlike the other drugs used in osteoporosis, it acts by stimulating new bone formation in both the spine and the hip. Given as a daily injection for up to 24 months, it increases bone tissue and bone strength, and has been shown to reduce the risk of spine and other fractures.
Side effects include nausea, dizziness and leg cramps.
It also has a black box warning from the FDA because of the small possibility that it may increase risk of developing osteosarcoma. Because of this risk, it should not use unless there is osteoporosis and at least one of the following conditions is met: already had at least one bone fracture; it is determined that there is high risk of fractures; or contraindicated or do not respond to other medications for osteoporosis.
Estrogen/Hormone Therapy (ET/HT)
ET/HT has been shown to reduce bone loss, increase bone density in both the spine and hip, and reduce the risk of spine and hip fractures in postmenopausal women. When estrogen -also known as estrogen therapy or ET -is taken alone, it can increase a woman's risk of developing endometrial cancer. To eliminate this risk, progestin is used in combination with estrogen for those women who have not had a hysterectomy.
Side effects of ET/HT include vaginal bleeding, breast tenderness, mood disturbances, blood clots in the veins, and gallbladder disease.
Because of recent evidence that breast cancer, strokes, blood clots, and heart attacks may be increased in some women who take estrogen, the FDA recommends the lowest effective dose for the shortest period possible. Estrogen should only be considered if there is significant risk for osteoporosis and other drugs are not suitable. Approximately 14,000 people die per year from osteoporosis (greater than carcinoma of ovary, uterus and cervix put together).The mortality of hip fracture in older patients is 20% at three months.
Postmenopausal Osteoporosis
Only 50% of survivors regain full independence after fracture.
Survivors consult their GP approximately nine extra times in the year following their fracture. Only one in three vertebral fractures is diagnosed.
One vertebral fracture increases a patient's risk of sustaining another vertebral fracture fivefold, 20% of these within a year.
Future Hope
Two new biologics (drugs synthesized from living organisms), Denosumab and Odanacatib, are within several years of FDA approval. Both target osteoclasts, which are the cells that break down bone to make way for new bone. These drugs hope to rebalance bone loss and bone building so the two processes function properly.
DenosumabA human antibody, it targets receptor activator of nuclear factor kappa b ligand (RANKL), a protein that acts as the primary signal to promote bone removal. In individuals with osteoporosis, RANKL overwhelms the body's natural defense against bone destruction.
Completed last September, the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study, a large phase 3 trial of Denosumab with more than 7,000 participants, yielded impressive results (15). The drug was well tolerated with no major shortterm side effects and showed reductions in both hip and spine fractures.
Questions remain about long-term side effects, and it will take time following the drug's approval to determine its overall success compared with other currently available treatments.
Odanacatib is not as far along as Donosumab, with its phase 3 trials just getting underway, but initial results from a phase 2b trial appear positive. In a multicenter, double-blind, randomized, placebo-controlled study in postmenopausal women with low bone mineral density, the subjects took an Odanacatib or a placebo once per week and found that two years later, the women who took the drug had significant gains in bone mineral density in the lumbar spine and hip. The biologic approach in this drug targets an enzyme called cathepsin K to reduce osteoclast activity.
Awareness Remains Key
An improved diet, a fall-prevention exercise class, dietary supplements such as vitamin D and calcium, and one or 
Conclusions
The prevention of osteoporosis should begin early and continue all the way through life with measures that improve or maintain bone health including regular physical activity and a balanced diet, considering not only an adequate intake of calcium but also of other minerals, proteins, and food rich in antioxidants.
Smoking and alcohol abuse should be avoided. In older persons, who are particularly at risk of fragility fractures, the prevention of falls and the maintenance of an adequate vitamin D status are essential. Assessment of fracture risk followed by proved effective nonpharmacological and pharmacological management strategies should always be implemented.
